431 related articles for article (PubMed ID: 34168406)
1. Role of imaging in evaluating the response after neoadjuvant treatment for pancreatic ductal adenocarcinoma.
Zhang Y; Huang ZX; Song B
World J Gastroenterol; 2021 Jun; 27(22):3037-3049. PubMed ID: 34168406
[TBL] [Abstract][Full Text] [Related]
2. High-resolution pancreatic computed tomography for assessing pancreatic ductal adenocarcinoma resectability: a multicenter prospective study.
Lee DH; Ha HI; Jang JY; Lee JW; Choi JY; Bang S; Lee CH; Kim WB; Lee SS; Kim SC; Kang BK; Lee JM
Eur Radiol; 2023 Sep; 33(9):5965-5975. PubMed ID: 36988715
[TBL] [Abstract][Full Text] [Related]
3. Imaging Assessment of Pancreatic Cancer Resectability After Neoadjuvant Therapy:
Soloff EV; Al-Hawary MM; Desser TS; Fishman EK; Minter RM; Zins M
AJR Am J Roentgenol; 2022 Apr; 218(4):570-581. PubMed ID: 34851713
[TBL] [Abstract][Full Text] [Related]
4. Prediction of margin-negative resection of pancreatic ductal adenocarcinoma following neoadjuvant therapy: Diagnostic performance of NCCN criteria for resection vs CT-determined resectability.
Jang JK; Choi SJ; Byun JH; Kim JH; Lee SS; Kim HJ; Yoo C; Kim KP; Hong SM; Seo DW; Hwang DW; Kim SC
J Hepatobiliary Pancreat Sci; 2022 Sep; 29(9):1025-1034. PubMed ID: 35658103
[TBL] [Abstract][Full Text] [Related]
5. Application of Magnetic Resonance Imaging in Neoadjuvant Treatment of Pancreatic Ductal Adenocarcinoma.
Qu C; Zeng PE; Wang HY; Yuan CH; Yuan HS; Xiu DR
J Magn Reson Imaging; 2022 Jun; 55(6):1625-1632. PubMed ID: 35132729
[TBL] [Abstract][Full Text] [Related]
6. FDG-PET Predicts Neoadjuvant Therapy Response and Survival in Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma.
Abdelrahman AM; Goenka AH; Alva-Ruiz R; Yonkus JA; Leiting JL; Graham RP; Merrell KW; Thiels CA; Hallemeier CL; Warner SG; Haddock MG; Grotz TE; Tran NH; Smoot RL; Ma WW; Cleary SP; McWilliams RR; Nagorney DM; Halfdanarson TR; Kendrick ML; Truty MJ
J Natl Compr Canc Netw; 2022 Sep; 20(9):1023-1032.e3. PubMed ID: 36075389
[TBL] [Abstract][Full Text] [Related]
7. Critical issues in pathologic evaluation of pancreatic ductal adenocarcinoma resected after neoadjuvant treatment: a narrative review.
Taherian M; Wang H
Chin Clin Oncol; 2022 Jun; 11(3):21. PubMed ID: 35726190
[TBL] [Abstract][Full Text] [Related]
8. Usefulness of
Yokose T; Kitago M; Matsusaka Y; Masugi Y; Shinoda M; Yagi H; Abe Y; Oshima G; Hori S; Endo Y; Toyama K; Iwabuchi Y; Takemura R; Ishii R; Nakahara T; Okuda S; Jinzaki M; Kitagawa Y
Cancer Med; 2020 Jun; 9(12):4059-4068. PubMed ID: 32281301
[TBL] [Abstract][Full Text] [Related]
9. Response assessment in pancreatic ductal adenocarcinoma: role of imaging.
Baliyan V; Kordbacheh H; Parakh A; Kambadakone A
Abdom Radiol (NY); 2018 Feb; 43(2):435-444. PubMed ID: 29243123
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant Chemotherapy in Pancreatic Cancer: An Appraisal of the Current High-Level Evidence.
Müller PC; Frey MC; Ruzza CM; Nickel F; Jost C; Gwerder C; Hackert T; Z'graggen K; Kessler U
Pharmacology; 2021; 106(3-4):143-153. PubMed ID: 32966993
[TBL] [Abstract][Full Text] [Related]
11. Delta Radiomic Features Predict Resection Margin Status and Overall Survival in Neoadjuvant-Treated Pancreatic Cancer Patients.
Wang K; Karalis JD; Elamir A; Bifolco A; Wachsmann M; Capretti G; Spaggiari P; Enrico S; Balasubramanian K; Fatimah N; Pontecorvi G; Nebbia M; Yopp A; Kaza R; Pedrosa I; Zeh H; Polanco P; Zerbi A; Wang J; Aguilera T; Ligorio M
Ann Surg Oncol; 2024 Apr; 31(4):2608-2620. PubMed ID: 38151623
[TBL] [Abstract][Full Text] [Related]
12. Surgery after FOLFIRINOX treatment for locally advanced and borderline resectable pancreatic cancer: increase in tumour attenuation on CT correlates with R0 resection.
Marchegiani G; Todaro V; Boninsegna E; Negrelli R; Sureka B; Bonamini D; Salvia R; Manfredi R; Pozzi Mucelli R; Bassi C
Eur Radiol; 2018 Oct; 28(10):4265-4273. PubMed ID: 29679211
[TBL] [Abstract][Full Text] [Related]
13. CT prediction of resectability and prognosis in patients with pancreatic ductal adenocarcinoma after neoadjuvant treatment using image findings and texture analysis.
Kim BR; Kim JH; Ahn SJ; Joo I; Choi SY; Park SJ; Han JK
Eur Radiol; 2019 Jan; 29(1):362-372. PubMed ID: 29931561
[TBL] [Abstract][Full Text] [Related]
14. CT in the prediction of margin-negative resection in pancreatic cancer following neoadjuvant treatment: a systematic review and meta-analysis.
Park S; Jang JK; Byun JH; Kim JH; Lee SS; Kim HJ; Hong SB; Park SH
Eur Radiol; 2021 May; 31(5):3383-3393. PubMed ID: 33123793
[TBL] [Abstract][Full Text] [Related]
15. Assessment of Response to Neoadjuvant Therapy Using CT Texture Analysis in Patients With Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma.
Borhani AA; Dewan R; Furlan A; Seiser N; Zureikat AH; Singhi AD; Boone B; Bahary N; Hogg ME; Lotze M; Zeh HJ; Tublin ME
AJR Am J Roentgenol; 2020 Feb; 214(2):362-369. PubMed ID: 31799875
[No Abstract] [Full Text] [Related]
16. Preceding Systemic Chemotherapy for Patients with Pancreatic Ductal Adenocarcinoma with Positive Peritoneal Cytology Provides Survival Benefit Compared with Up-Front Surgery.
Ariake K; Mizuma M; Motoi F; Maeda S; Morikawa T; Ishida M; Ohtsuka H; Aoki S; Miura T; Takadate T; Nakagawa K; Kamei T; Unno M
Ann Surg Oncol; 2021 Oct; 28(11):6246-6254. PubMed ID: 33611747
[TBL] [Abstract][Full Text] [Related]
17. Overview and Future Perspectives on Tumor-Targeted Positron Emission Tomography and Fluorescence Imaging of Pancreatic Cancer in the Era of Neoadjuvant Therapy.
van Dam MA; Vuijk FA; Stibbe JA; Houvast RD; Luelmo SAC; Crobach S; Shahbazi Feshtali S; de Geus-Oei LF; Bonsing BA; Sier CFM; Kuppen PJK; Swijnenburg RJ; Windhorst AD; Burggraaf J; Vahrmeijer AL; Mieog JSD
Cancers (Basel); 2021 Dec; 13(23):. PubMed ID: 34885196
[TBL] [Abstract][Full Text] [Related]
18. White paper on pancreatic ductal adenocarcinoma from society of abdominal radiology's disease-focused panel for pancreatic ductal adenocarcinoma: Part II, update on imaging techniques and screening of pancreatic cancer in high-risk individuals.
Kulkarni NM; Mannelli L; Zins M; Bhosale PR; Arif-Tiwari H; Brook OR; Hecht EM; Kastrinos F; Wang ZJ; Soloff EV; Tolat PP; Sangster G; Fleming J; Tamm EP; Kambadakone AR
Abdom Radiol (NY); 2020 Mar; 45(3):729-742. PubMed ID: 31768594
[TBL] [Abstract][Full Text] [Related]
19. The Role of 18F-FDG PET/CT and PET/MRI in Pancreatic Ductal Adenocarcinoma.
Yeh R; Dercle L; Garg I; Wang ZJ; Hough DM; Goenka AH
Abdom Radiol (NY); 2018 Feb; 43(2):415-434. PubMed ID: 29143875
[TBL] [Abstract][Full Text] [Related]
20. Risk Stratification of Pancreatic Ductal Adenocarcinoma Patients Undergoing Curative-Intent Surgery after Neoadjuvant Therapy.
Yang HK; Park MS; Han K; Eom G; Chung YE; Choi JY; Bang S; Kang CM; Seong J; Kim MJ
Cancer Res Treat; 2024 Jan; 56(1):247-258. PubMed ID: 37605535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]